WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001002432) SH3-CONTAINING PROTEIN, DNA AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/002432    International Application No.:    PCT/US2000/018304
Publication Date: 11.01.2001 International Filing Date: 30.06.2000
Chapter 2 Demand Filed:    31.01.2001    
IPC:
C07K 14/47 (2006.01)
Applicants: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS [US/US]; 2404 North University Avenue, Little Rock, AR 72207 (US) (For All Designated States Except US).
O'BRIEN, Timothy, J. [US/US]; (US) (For US Only).
WANG, Yinxiang [CN/US]; (US) (For US Only)
Inventors: O'BRIEN, Timothy, J.; (US).
WANG, Yinxiang; (US)
Agent: ADLER, Benjamin, A.; McGregor & Adler, 8011 Candle Ln., Houston, TX 77071 (US)
Priority Data:
09/346,510 01.07.1999 US
Title (EN) SH3-CONTAINING PROTEIN, DNA AND USES THEREOF
(FR) PROTEINE CONTENANT SH3, ADN ET UTILISATIONS ASSOCIEES
Abstract: front page image
(EN)The present invention encompasses an SH3 domain-containing TADG5 (CGBP1) protein (SEQ ID No. 1), allelic variants of functional fragments thereof, a novel TADG5 DNA segment (SEQ ID No. 2) coding for the TADG5 protein, allelic variants or functional fragments thereof, chimeric cells comprising the TADG5 DNA segment, expression vectors and plasmids comprising the TADG5 DNA segment and methods for producing the TADG5 protein. The present invention further encompasses methods of using the TADG5 protein (e.g., for gene regulation, etc.).
(FR)La présente invention concerne une protéine contenant le domaine SH3 TADG5 (CGBP1) (SEQ ID No. 1), des variants alléliques de fragments fonctionnels de cette dernière, un nouveau segment TADG5 d'ADN (SEQ ID No. 2) codant la protéine TADG5, des variants alléliques ou des fragments fonctionnels de cette dernière, des cellules chimériques comprenant le segment ADN TADG5, des vecteurs d'expression et des plasmides comprenant le segment ADN TADG5 et des procédés de production de la protéine TADG5. La présente invention concerne également des procédés d'utilisation de la protéine TADG5 (par exemple, pour le contrôle de l'expression génique, etc.).
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)